CHIL’s High-Risk Group EIA Kits Recognized as Reference Assays in KSA Screening Program
CHIL’s high-risk group HIVAb, HBsAg, and HCVAb Enzyme Immunoassay (EIA) diagnostic kits have gained recognition as reference assays within a…
CHIL Continued Its Regional Engagement at Arab Health
From January 25–28, 2016, CHIL participated in Arab Health in Dubai, further advancing its activities within the regional healthcare market.…
CHIL Engaged with Global Industry Leaders at MEDICA 2015
From November 16–19, 2015, CHIL participated in MEDICA Messe Düsseldorf in Düsseldorf, Germany, joining one of the most influential gatherings…
CE Certification Obtained for In-Vitro Diagnostic Rapid Test Portfolio; ISO 9001 and ISO 13485 Renewed
On August 17, 2015, CHIL successfully obtained CE certification from a European Notified Body for its in-vitro diagnostic product portfolio,…
First Export to KSA for High-Risk Group Screening Project
On March 16, 2015, CHIL completed its first export to the Kingdom of Saudi Arabia under a screening project involving…
CHIL at Arab Health 2015, Dubai
From January 26–29, 2015, CHIL once again participated in Arab Health in Dubai, maintaining its active presence in one of…
CHIL Registered with SFDA in Saudi Arabia
On January 6, 2015, CHIL was officially registered with the Saudi Food and Drug Authority (SFDA) through its local partner…
CHIL Returned to MEDICA
CHIL participated in MEDICA Messe Düsseldorf held on November 12–15, 2014, in Düsseldorf, Germany. By once again taking part in…
Turnkey Rapid Test Production Project Completed in Italy
In May 2014, CHIL successfully completed a comprehensive turnkey project for a company in Italy. The engagement covered the establishment…
CHIL Showcased Its Portfolio at Arab Health
From January 27–30, 2014, CHIL participated in Arab Health in Dubai, presenting its diagnostic product portfolio to a broad international…